ALLR Latest Press Releases

-- September 30, 2026 --

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor to Drive Stenoparib's Clinical Development Globe Newswire 9:00 AM

-- September 28, 2026 --

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research Globe Newswire 8:00 AM

-- September 15, 2026 --

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP Companion Diagnostic, Further Strengthening Stenoparib Development Globe Newswire 8:00 AM

-- September 11, 2026 --

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement Globe Newswire 8:00 AM

-- August 14, 2026 --

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign Globe Newswire 8:00 AM

-- July 7, 2026 --

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP Testing for FDA Registration Globe Newswire 8:00 AM

-- June 30, 2026 --

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP Companion Diagnostic Globe Newswire 8:00 AM

-- June 18, 2026 --

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes